$93.7 Million is the total value of Nan Fung Group Holdings Ltd's 44 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 20.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ILMN | ILLUMINA INC | $12,441,678 | -24.0% | 119,196 | 0.0% | 13.27% | -12.5% | |
HRMY | HARMONY BIOSCIENCES HLDGS IN | $11,122,623 | -10.2% | 368,665 | 0.0% | 11.87% | +3.5% | |
MRUS | Buy | MERUS N V | $7,102,648 | +76.2% | 120,038 | +34.1% | 7.58% | +102.9% |
GERN | Buy | GERON CORP | $5,823,852 | +33.2% | 1,373,550 | +3.7% | 6.21% | +53.4% |
OCULIS HOLDING AGordinary shares | $5,214,717 | -0.8% | 436,378 | 0.0% | 5.56% | +14.2% | ||
INCY | INCYTE CORP | $4,487,214 | +6.4% | 74,022 | 0.0% | 4.79% | +22.5% | |
EXSCIENTIA PLCads | $4,385,449 | -10.8% | 859,892 | 0.0% | 4.68% | +2.7% | ||
XENE | XENON PHARMACEUTICALS INC | $4,159,453 | -9.4% | 106,680 | 0.0% | 4.44% | +4.3% | |
LBPH | Buy | LONGBOARD PHARMACEUTICALS IN | $3,907,727 | +53.0% | 144,570 | +22.3% | 4.17% | +76.1% |
MIRM | Buy | MIRUM PHARMACEUTICALS INC | $3,627,559 | +50.3% | 106,100 | +10.4% | 3.87% | +73.0% |
FLDM | STANDARD BIOTOOLS INC | $3,333,227 | -34.7% | 1,883,179 | 0.0% | 3.56% | -24.8% | |
BGNE | BEIGENE LTDsponsored adr | $3,284,549 | -8.8% | 23,022 | 0.0% | 3.50% | +5.0% | |
KALV | KALVISTA PHARMACEUTICALS INC | $2,583,083 | -0.7% | 219,277 | 0.0% | 2.76% | +14.4% | |
RYTM | RHYTHM PHARMACEUTICALS INC | $2,016,867 | -5.2% | 49,120 | 0.0% | 2.15% | +9.1% | |
Buy | TOURMALINE BIO INC | $1,887,848 | +292.8% | 146,800 | +599.5% | 2.01% | +352.6% | |
RANI THERAPEUTICS HLDGS INC | $1,875,619 | +22.2% | 493,584 | 0.0% | 2.00% | +40.7% | ||
ASND | ASCENDIS PHARMA A/Ssponsored adr | $1,854,768 | -9.8% | 13,600 | 0.0% | 1.98% | +3.9% | |
REPL | REPLIMUNE GROUP INC | $1,844,451 | +10.2% | 204,939 | 0.0% | 1.97% | +26.9% | |
ACAD | ACADIA PHARMACEUTICALS INC | $1,673,490 | -12.1% | 102,984 | 0.0% | 1.78% | +1.2% | |
MDGL | MADRIGAL PHARMACEUTICALS INC | $1,591,869 | +4.9% | 5,682 | 0.0% | 1.70% | +20.8% | |
EXEL | EXELIXIS INC | $1,442,574 | -5.3% | 64,200 | 0.0% | 1.54% | +9.0% | |
ZLAB | New | ZAI LAB LTDadr | $953,150 | – | 55,000 | +100.0% | 1.02% | – |
BMRN | BIOMARIN PHARMACEUTICAL INC | $890,399 | -5.7% | 10,815 | 0.0% | 0.95% | +8.6% | |
BOLT | BOLT BIOTHERAPEUTICS INC | $875,214 | -46.4% | 1,166,952 | 0.0% | 0.93% | -38.3% | |
ENTRADA THERAPEUTICS INC | $699,419 | +0.6% | 49,082 | 0.0% | 0.75% | +15.8% | ||
ATHA | ATHIRA PHARMA INC | $477,000 | -3.3% | 180,000 | 0.0% | 0.51% | +11.4% | |
PACB | PACIFIC BIOSCIENCES CALIF IN | $376,049 | -63.5% | 274,488 | 0.0% | 0.40% | -58.0% | |
CABA | CABALETTA BIO INC | $352,682 | -56.2% | 47,150 | 0.0% | 0.38% | -49.5% | |
BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $350,152 | – | 17,300 | +100.0% | 0.37% | – |
ROIVANT SCIENCES LTD | $343,208 | +0.3% | 32,470 | 0.0% | 0.37% | +15.5% | ||
KYMR | KYMERA THERAPEUTICS INC | $324,619 | -25.7% | 10,875 | 0.0% | 0.35% | -14.6% | |
New | GRAIL INC | $305,340 | – | 19,866 | +100.0% | 0.33% | – | |
RVMD | REVOLUTION MEDICINES INC | $283,313 | +20.4% | 7,300 | 0.0% | 0.30% | +38.5% | |
SWTX | SPRINGWORKS THERAPEUTICS INC | $280,642 | -23.5% | 7,450 | 0.0% | 0.30% | -12.1% | |
ALXO | ALX ONCOLOGY HLDGS INC | $252,959 | -45.9% | 41,950 | 0.0% | 0.27% | -37.6% | |
IMCR | IMMUNOCORE HLDGS PLCads | $228,758 | -47.9% | 6,750 | 0.0% | 0.24% | -40.0% | |
AFFIMED N V | $202,996 | +2.8% | 37,247 | 0.0% | 0.22% | +18.6% | ||
IMTX | IMMATICS N.V | $182,434 | +10.6% | 15,700 | 0.0% | 0.20% | +27.5% | |
BMEA | BIOMEA FUSION INC | $180,000 | -69.9% | 40,000 | 0.0% | 0.19% | -65.3% | |
ABCL | ABCELLERA BIOLOGICS INC | $150,874 | -34.7% | 50,971 | 0.0% | 0.16% | -24.8% | |
New | DBV TECHNOLOGIES S Asponsored adr | $148,565 | – | 185,475 | +100.0% | 0.16% | – | |
AVTE | AEROVATE THERAPEUTICS INC | $79,574 | -94.4% | 47,936 | 0.0% | 0.08% | -93.5% | |
KOD | KODIAK SCIENCES INC | $75,017 | -55.3% | 31,922 | 0.0% | 0.08% | -48.7% | |
FGEN | FIBROGEN INC | $55,417 | -62.0% | 62,106 | 0.0% | 0.06% | -56.3% | |
GRTX | Exit | GALERA THERAPEUTICS INC | $0 | – | -613,223 | -100.0% | -0.08% | – |
BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -36,847 | -100.0% | -0.17% | – |
DBVT | Exit | DBV TECHNOLOGIES S Asponsored adr | $0 | – | -370,950 | -100.0% | -0.26% | – |
Exit | NEUMORA THERAPEUTICS INC. | $0 | – | -63,315 | -100.0% | -0.81% | – | |
ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -263,940 | -100.0% | -9.69% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
HARMONY BIOSCIENCES HLDGS IN | 13 | Q2 2024 | 21.3% |
XENON PHARMACEUTICALS INC | 13 | Q2 2024 | 4.4% |
BOLT BIOTHERAPEUTICS INC | 13 | Q2 2024 | 5.6% |
KALVISTA PHARMACEUTICALS INC | 13 | Q2 2024 | 2.8% |
EXELIXIS INC | 13 | Q2 2024 | 1.5% |
ALX ONCOLOGY HLDGS INC | 13 | Q2 2024 | 1.0% |
ILLUMINA INC | 12 | Q2 2024 | 21.5% |
RANI THERAPEUTICS HLDGS INC | 12 | Q2 2024 | 3.5% |
GALERA THERAPEUTICS INC | 12 | Q1 2024 | 1.9% |
DBV TECHNOLOGIES S A | 12 | Q1 2024 | 0.6% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-11-13 |
N-PX | 2024-08-30 |
13F-HR | 2024-08-13 |
13F-HR | 2024-05-14 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-13 |
SC 13D/A | 2022-12-16 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.